AVAI (Avai Bio) 12-1 Month Momentum %: -71.78% (As of Jul. 13, 2026)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.15
! 3 Warning Signs
View Full Analysis

What is Avai Bio 12-1 Month Momentum %?

Avai Bio AVAI -14.23% 24 12-1 Month Momentum % is -71.78% as of Jul. 13, 2026. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,768 Software companies, Avai Bio ranks worse than 94.62% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-13), Avai Bio's 12-1 Month Momentum % is -71.78%.

The industry rank for Avai Bio's 12-1 Month Momentum % or its related term are showing as below:

AVAI's 12-1 Month Momentum % is ranked worse than
94.62% of 2768 companies
in the Software industry
Industry Median: -19.53 vs AVAI: -71.78

Avai Bio  (OTCPK:AVAI) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Avai Bio 12-1 Month Momentum % Related Terms

AVAI vs IPM, RCT, LPSN: 12-1 Month Momentum % Comparison

For the Software - Application subindustry, Avai Bio's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avai Bio 12-1 Month Momentum % vs Software Industry

For the Software industry and Technology sector, Avai Bio's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Avai Bio's 12-1 Month Momentum % falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio  (OTCPK:AVAI) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -71.78% mean?
Avai Bio (AVAI) has a 12-1 Month Momentum % of -71.78% as of Jul. 13, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #2619 out of 2768 companies in the Software industry, placing it in the top 94.6%.
Is Avai Bio's 12-1 Month Momentum % too high?
Avai Bio's current 12-1 Month Momentum % is -71.78%. Based on the distribution chart, Avai Bio ranks #2619 out of 2768 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's 12-1 Month Momentum % compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #2619 out of 2768 companies for 12-1 Month Momentum %. This places Avai Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Software company?
A good 12-1 Month Momentum % depends on the Software industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Avai Bio and its competitors. Avai Bio's current 12-1 Month Momentum % is -71.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current 12-1 Month Momentum % of -71.78%. The current 12-1 Month Momentum % is -71.78%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Avai Bio (AVAI), the current 12-1 Month Momentum % is -71.78% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price